



BRUST-ZENTRUM ZÜRICH

Dr. med Magdalena Pircher

Fachärztin FMH für Medizinische Onkologie

T +41 44 533 81 32

m.pircher@brust-zentrum.ch

Publikationsliste

- Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.

Lutz-Nicoladoni C, Wallner S, Stoitzner P, Pircher M, Gruber T, Wolf AM, Gastl G, Penninger JM, Baier G, Wolf D

Immunol Cell Biol. 2012 Jan;90(1):130-4. doi: 10.1038/icb.2011.11. Epub 2011 Mar 8.

- Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.

Gampenrieder SP, Romeder F, Muß C, Pircher M, Ressler S, Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, Greil R.

Anticancer Res. 2014 Jan;34(1):227-33.

- Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.

Pircher M, Mlineritsch B, Fridrik MA, Dittrich C, Lang A, Petru E, Weltermann A, Thaler J, Hufnagl C, Gampenrieder SP, Rinnerthaler G, Ressler S, Ulmer H, Greil R

Anticancer Res. 2015 Jan;35(1):517-21.

- T Cell Engineering.

Pircher M, Schirrmann, Petrausch U.

Prog Tumor Res. 2015 Sep;42:110-35.

- Ovarian Hyperstimulation and Oocyte Harvesting Prior to Systemic Chemotherapy—A Possible Pitfall in 18F-FDG PET/CT Staging of Oncologic Patients.

Bacanovic S, Stiller R, Pircher M, Burger IA, Huellner MW.

Clin Nucl Med. 2016 Aug;41(8):e394-6.



BRUST-ZENTRUM
ZÜRICH

- Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
Gulati P, Rühl J, Kannan A, Pircher M, Schuberth P, Nytko KJ, Pruschy M, Sulser S, Haefner M, Jensen S, Soltermann A, Jungraithmayr W, Eisenring M, Winder T, Samaras P, Tabor A, Stenger R, Stupp R, Weder W, Renner C, Münz C, Petrusch U; Clin Cancer Res. 2018 Aug 15;24(16):3981–3993

Brust-Zentrum AG

Seefeldstrasse 214
CH-8008 Zürich

T +41 44 533 81 00
info@brust-zentrum.ch